This post was originally published on this site A large-scale screening provided a system to prioritize gene targets for the potential development of tailored cancer therapies. According to the scientists, the findings may also help produce the Cancer Dependency Map, a comprehensive rulebook for the precision treatment of cancer. The study, “Prioritisation of cancer therapeutic…

This post was originally published on this site Using an advanced microscopic technique to visualize how CAR T cells work in a mouse model of lymphoma, researchers found that these cells can induce tumor regression by directly targeting and killing cancer cells but there is significant diversity in how they behave in an animal. The study,…

This post was originally published on this site PureTech Health is developing two promising candidate therapies that target key immunosuppressive mechanisms in cancer and may be used against cancers that fail to respond to existing immunotherapy approaches. The antibodies — LYT-200 and LYT-210 — were developed to inhibit the Galectin-9 protein and gamma delta 1 (γδ1)…

This post was originally published on this site Aiming to improve lenalidomide‘s safety and efficacy, ChemioCare is setting up to develop a new treatment formulation delivered through a skin patch, maintaining an optimal blood level of the medicine for prolonged periods of time. The new formulation uses the company’s permeation-enhanced transdermal technology (PETT), which “works like a…

This post was originally published on this site Breast cancer surgery with negative or clear margins, which leaves no signs of cancer behind, stimulates a protective anticancer immune response that reduces the risk of cancer spread to other regions in the body, a mouse study suggests. Researchers are now studying if the molecular culprits involved in…

This post was originally published on this site A combination of androgen deprivation therapy (ADT) and external beam radiation therapy (EBRT) is better at delaying disease progression and extending survival of patients with locally advanced prostate cancer than ADT alone, a Phase 3 trial shows. The study, “Long‐term androgen deprivation, with or without radiotherapy, in…

This post was originally published on this site Aprea Therapeutics‘ APR-246 stabilizes the tumor suppressor protein p53, boosting responses to checkpoint blockade immunotherapies in mouse models of melanoma and colorectal cancer, a study says. Findings were announced in a press release and featured on the poster, “TP53-stabilization with APR-246 enhances antitumor effects of immune checkpoint blockade…

This post was originally published on this site Treatment with a liposomal formulation of irinotecan — meaning the chemotherapy is wrapped up in tiny fatty spheres —was well-tolerated and partially reduced the tumor burden in 35% of heavily pretreated breast cancer patients in a Phase 1 clinical trial, including those with brain metastasis. Results were…

This post was originally published on this site Lumicell is assessing its LUM Imaging System as a means to help surgeons better detect cancer cells that spread into the peritoneum — the membrane lining the abdominal cavity and covering the abdominal organs – during surgery, the company announced. The clinical trial (NCT03834272) — which is…

This post was originally published on this site The Multiple Myeloma Research Foundation (MMRF) has launched the Myeloma Investment Fund in an effort to attract promising biotech and technology companies to the multiple myeloma field and to advance new treatments. The $50 million independent, self-sustaining fund is focused on accelerating the foundation’s mission to deliver precision…

This post was originally published on this site Chronic B-cell activation — which can happen because of infectious mononucleosis, commonly caused by the Epstein-Barr virus (EBV) — triggers an excessive proliferation of certain B cells, which can evolve into a B-cell lymphoma. Although such chronic activation alone is not sufficient to drive cancer onset, vaccinating against EBV may work to…

This post was originally published on this site Melanomas with a high number of genetic mutations that lead to over-activation of the nuclear factor-κB (NF-κB) signaling cascade — a family of gene expression regulators — are about three times more likely to respond to treatment with checkpoint blockade immunotherapies, according to a study. The findings…